Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 17;12(9):1452.
doi: 10.3390/antibiotics12091452.

Predicting Extended-Spectrum Beta-Lactamase and Carbapenem Resistance in Enterobacteriaceae Bacteremia: A Diagnostic Model Systematic Review and Meta-Analysis

Tristan T Timbrook  1   2 , McKenna J Fowler  1
Affiliations
Review

Predicting Extended-Spectrum Beta-Lactamase and Carbapenem Resistance in Enterobacteriaceae Bacteremia: A Diagnostic Model Systematic Review and Meta-Analysis

Tristan T Timbrook et al. Antibiotics (Basel). .

Abstract

Enterobacteriaceae bacteremia, particularly when associated with antimicrobial resistance, can result in increased mortality, emphasizing the need for timely effective therapy. Clinical risk prediction models are promising tools, stratifying patients based on their risk of resistance due to ESBL and carbapenemase-producing Enterobacteriaceae in bloodstream infections (BSIs) and, thereby, improving therapeutic decisions. This systematic review and meta-analysis synthesized the literature on the performance of these models. Searches of PubMed and EMBASE led to the identification of 10 relevant studies with 6106 unique patient encounters. Nine studies concerned ESBL prediction, and one focused on the prediction of carbapenemases. For the two ESBL model derivation studies, the discrimination performance showed sensitivities of 53-85% and specificities of 93-95%. Among the four ESBL model derivation and validation studies, the sensitivities were 43-88%, and the specificities were 77-99%. The sensitivity and specificity for the subsequent external validation studies were 7-37% and 88-96%, respectively. For the three external validation studies, only two models were evaluated across multiple studies, with a pooled AUROC of 65-71%, with one study omitting the sensitivity/specificity. Only two studies measured clinical utility through hypothetical therapy assessments. Given the limited evidence on their interventional application, it would be beneficial to further assess these or future models, to better understand their clinical utility and ensure their safe and impactful implementation.

Keywords: ESBL production; Enterobacteriaceae bacteremia; antimicrobial resistance; antimicrobial stewardship; carbapenemase production; clinical utility of predictive models; risk prediction scoring systems.

PubMed Disclaimer

Conflict of interest statement

T.T.T. is an employee and shareholder of bioMérieux, an in vitro diagnostics company.

Figures

Figure 1
Figure 1
The study selection procedure.
Figure 2
Figure 2
The discrimination performance of ESBL prediction models studies.
Figure 3
Figure 3
The pooled discrimination performance of external validations. (a) Augustine 2017 [10] ESBL model. (b) Lee 2017 [15] ESBL model.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. CDC . Antibiotic Resistance Threats in the United States. U.S. Department of Health and Human Services; Atlanta, GA, USA: 2019.
    1. van Duin D., Paterson D.L. Multidrug-Resistant Bacteria in the Community: An Update. Infect. Dis. Clin. N. Am. 2020;34:709–722. doi: 10.1016/j.idc.2020.08.002. - DOI - PMC - PubMed
    1. Serwecińska L. Antimicrobials and Antibiotic-Resistant Bacteria: A Risk to the Environment and to Public Health. Water. 2020;12:3313. doi: 10.3390/w12123313. - DOI
    1. Cizman M., Plankar Srovin T. Antibiotic consumption and resistance of gram-negative pathogens (collateral damage) GMS Infect. Dis. 2018;6:Doc05. doi: 10.3205/id000040. - DOI - PMC - PubMed
    1. Smith R.A., M’Ikanatha N M., Read A.F. Antibiotic resistance: A primer and call to action. Health Commun. 2015;30:309–314. doi: 10.1080/10410236.2014.943634. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources